A Phase II Study of Lenvatinib Monotherapy as Second-Line Treatment in Unresectable Biliary Tract Cancer: Primary Analysis Results

被引：0

作者：

Ikeda, Masafumi ^{[1
]}

Sasaki, Takashi ^{[2
]}

Morizane, Chigusa ^{[3
]}

Mizuno, Nobumasa ^{[4
]}

Nagashima, Fumio ^{[5
]}

Shimizu, Satoshi ^{[6
]}

Hayata, Nozomi ^{[7
]}

Ikezawa, Hiroki ^{[7
]}

Suzuki, Takuya ^{[7
]}

Nakajima, Ryo ^{[7
]}

Dutcus, Corina E. ^{[8
]}

Bower, John ^{[9
]}

Ueno, Makoto ^{[10
]}

机构：

[1] Hosp East, Natl Canc Ctr, Kashiwa, Chiba, Japan

[2] JFCR, Canc Inst Hosp, Tokyo, Japan

[3] Natl Canc Ctr, Tokyo, Japan

[4] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[5] Kyorin Univ, Tokyo, Japan

[6] Saitama Canc Ctr, Saitama, Japan

[7] Eisai & Co Ltd, Tokyo, Japan

[8] Eisai Inc, Woodcliff Lake, NJ USA

[9] Eisai Australia Pty Ltd, Melbourne, Vic, Australia

[10] Kanagawa Canc Ctr Hosp, Yokohama, Kanagawa, Japan

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 13卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

151

引用

页码：115 / 115

页数：1

共 50 条

[1] Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results
Ueno, Makoto
Ikeda, Masafumi
Sasaki, Takashi
Nagashima, Fumio
Mizuno, Nobumasa
Shimizu, Satoshi
Ikezawa, Hiroki
Hayata, Nozomi
Nakajima, Ryo
Morizane, Chigusa
BMC CANCER, 2020, 20 (01)
[2] A phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: Primary analysis results
Ikeda, M.
Sasaki, T.
Morizane, C.
Mizuno, N.
Nagashima, F.
Shimizu, S.
Hayata, N.
Ikezawa, H.
Suzuki, T.
Nakajima, R.
Dutcus, C.
Ueno, M.
ANNALS OF ONCOLOGY, 2017, 28
[3] Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results
Makoto Ueno
Masafumi Ikeda
Takashi Sasaki
Fumio Nagashima
Nobumasa Mizuno
Satoshi Shimizu
Hiroki Ikezawa
Nozomi Hayata
Ryo Nakajima
Chigusa Morizane
BMC Cancer, 20
[4] Interim analysis of a phase 2 study of lenvatinib (LEN) monotherapy as second-line treatment in unresectable biliary tract cancer (BTC)
Morizane, Chigusa
Ueno, Makoto
Sasaki, Takashi
Nagashima, Fumio
Mizuno, Nobumasa
Shimizu, Satoshi
Hayata, Nozomi
Ikezawa, Hiroki
Suzuki, Takuya
Nakajima, Ryo
Dutcus, Corina E.
Ikeda, Masafumi
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[5] Phase II study of evofosfamide (TH-302) monotherapy as a second-line treatment in advanced biliary tract cancer
Yoon, J. S.
Lee, K-H.
Cheon, G. J.
Bang, Y-J.
Oh, D-Y.
ANNALS OF ONCOLOGY, 2018, 29
[6] A retrospective study for the significance of second-line therapy for unresectable or recurrent biliary tract cancer
Kawamoto, Yasuyuki
Komatsu, Yoshito
Yamamura, Takahiro
Saito, Rika
Ito, Ken
Nakano, Shintaro
Harada, Kazuaki
Yuki, Satoshi
Kuwatani, Masaki
Sakamoto, Naoya
ANNALS OF ONCOLOGY, 2021, 32 : S333 - S333
[7] Imatinib Mesylate for Palliative Second-Line Treatment of Advanced Biliary Tract Cancer: A Bicentric Phase II Study
Roth, Annekathrin
Schleyer, Eberhard
Schoppmeyer, Konrad
Kluge, Regine
Wittekind, Christian
Moessner, Joachim
Wiedmann, Marcus
ONKOLOGIE, 2011, 34 (8-9): : 469 - 470
[8] Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine
Sasaki, Takashi
Isayama, Hiroyuki
Nakai, Yousuke
Mizuno, Suguru
Yamamoto, Keisuke
Yagioka, Hiroshi
Yashima, Yoko
Kawakubo, Kazumichi
Kogure, Hirofumi
Togawa, Osamu
Matsubara, Saburo
Ito, Yukiko
Sasahira, Naoki
Hirano, Kenji
Tsujino, Takeshi
Toda, Nobuo
Tada, Minoru
Omata, Masao
Koike, Kazuhiko
INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 708 - 713
[9] Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine
Takashi Sasaki
Hiroyuki Isayama
Yousuke Nakai
Suguru Mizuno
Keisuke Yamamoto
Hiroshi Yagioka
Yoko Yashima
Kazumichi Kawakubo
Hirofumi Kogure
Osamu Togawa
Saburo Matsubara
Yukiko Ito
Naoki Sasahira
Kenji Hirano
Takeshi Tsujino
Nobuo Toda
Minoru Tada
Masao Omata
Kazuhiko Koike
Investigational New Drugs, 2012, 30 : 708 - 713
[10] A Retrospective Study of S-1 Monotherapy as Second-line Treatment for Patients with Advanced Biliary Tract Cancer
Kobayashi, Satoshi
Ueno, Makoto
Ohkawa, Shinichi
Andou, Tomoko
Kameda, Ryo
Yamamoto, Naoto
Morinaga, Soichiro
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (09) : 800 - 806

← 1 2 3 4 5 →